论文部分内容阅读
目的观察卡维地洛治疗慢性心力衰竭的临床效果。方法观察组:卡维地洛6.25～50mg,2次/d口服;对照组:倍他乐克6.25～50mg,1次/d口服。二组均同时服用雅施达4mg,1次/d口服,卡维地洛与倍他乐克均从小剂量用起,根据患者耐受情况每2周调整剂量,至最大耐受量。结果观察组有效率93.54%;对照组有效率83.87%,观察组较对照组疗效有显著性差异(P<0.05)。结论β受体阻滞剂(卡维地洛)优于选择性β1受体阻滞剂,能更有效改善心功能,提高患者的生存质量。
Objective To observe the clinical effect of carvedilol on chronic heart failure. Methods The observation group: carvedilol 6.25 ~ 50mg, 2 times / d orally; control group: Betaloc 6.25 ~ 50mg, 1 time / d orally. The two groups also took Asarum 4mg, 1 / d orally, carvedilol and metoprolol were used from a small dose, according to patient tolerance every 2 weeks to adjust the dose to the maximum tolerated dose. Results The effective rate of the observation group was 93.54%. The effective rate of the control group was 83.87%. There was significant difference between the observation group and the control group (P <0.05). Conclusion β-blocker (carvedilol) is superior to selective β1-blockers, which can improve cardiac function and improve the quality of life of patients.